Gene · 862
Papers4,591
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 4,591
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy. | Sci Rep | 2023 | 38071228 | PubTator, text mining | PubMed |
| Folate-Appended Hydroxypropyl-β-Cyclodextrin Induces Autophagic Cell Death in Acute Myeloid Leukemia Cells. | Int J Mol Sci | 2023 | 38069042 | PubTator, text mining | PubMed |
| Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies. | Int J Mol Sci | 2023 | 38069030 | PubTator, text mining | PubMed |
| Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world. | Cancer Med | 2023 | 38062912 | PubTator, text mining | PubMed |
| Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial. | Front Immunol | 2023 | 38054008 | PubTator, text mining | PubMed |
| Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. | Mol Cancer | 2023 | 38049829 | PubTator, text mining | PubMed |
| [The study of clinical characteristics and prognosis of RUNX1-RUNX1T1 positive acute myeloid leukemia based on next-generation sequencing]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 38049338 | PubTator, text mining | PubMed |
| [Expression characteristics and clinical significance of CD109 in de novo acute myeloid leukemia]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 38049323 | PubTator, text mining | PubMed |
| [Clinical characteristics and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia arising from malignant tumors]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 38049318 | PubTator, text mining | PubMed |
| Biology and genetics of extranodal mature T-cell and NKcell lymphomas and lymphoproliferative disorders. | Haematologica | 2023 | 38037802 | PubTator, text mining | PubMed |
| Clinical significance of WT1 in the evaluation of therapeutic effect and prognosis of non-M3 acute myeloid leukemia. | Cancer Biol Ther | 2023 | 38031921 | PubTator, text mining | PubMed |
| Untargeted metabolomic and lipidomic analyses reveal lipid dysregulation in the plasma of acute leukemia patients. | Front Mol Biosci | 2023 | 38028534 | PubTator, text mining | PubMed |
| Clinical Characteristics and Prognosis of Acute Myeloid Leukemia Patients with Protein Tyrosine Phosphatase Non-Receptor Type 11 Gene Mutation. | Pharmgenomics Pers Med | 2023 | 38023823 | PubTator, text mining | PubMed |
| Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML. | Front Oncol | 2023 | 38023260 | PubTator, text mining | PubMed |
| Prevalence and Prognosis of Secondary Genetic Aberrations Among Patients With Core Binding Factor Acute Myeloid Leukemia: A Mitelman Database Analysis. | World J Oncol | 2023 | 38022406 | PubTator, text mining | PubMed |
| Bidirectional interplay between metabolism and epigenetics in hematopoietic stem cells and leukemia. | EMBO J | 2023 | 38010205 | PubTator, text mining | PubMed |
| A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment. | Pharmaceuticals (Basel) | 2023 | 38004478 | PubTator, text mining | PubMed |
| A De Novo Frameshift Mutation in RPL5 with Classical Phenotype Abnormalities and Worsening Anemia Diagnosed in a Young Adult-A Case Report and Review of the Literature. | Medicina (Kaunas) | 2023 | 38004002 | PubTator, text mining | PubMed |
| Cytogenetics Is a Science, Not a Technique! Why Optical Genome Mapping Is So Important to Clinical Genetic Laboratories. | Cancers (Basel) | 2023 | 38001730 | PubTator, text mining | PubMed |
| Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML. | Cell Death Dis | 2023 | 37996430 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/862/papers?page=9